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Background: Epigenetic variation has been linked to several human diseases. Proliferative diabetic retinopathy
(PDR) is a major cause of vision loss in subjects with diabetes. However, studies examining the association between
PDR and the genome-wide DNA methylation pattern are lacking. Our aim was to identify epigenetic modifications
that associate with and predict PDR in subjects with type 1 diabetes (T1D).
Methods: DNA methylation was analyzed genome-wide in 485,577 sites in blood from cases with PDR (n = 28),
controls (n = 30), and in a prospective cohort (n = 7). False discovery rate analysis was used to correct the data for
multiple testing. Study participants with T1D diagnosed before 30 years of age and insulin treatment within 1 year
from diagnosis were selected based on 1) subjects classified as having PDR (cases) and 2) subjects with T1D who
had had diabetes for at least 10 years when blood DNA was sampled and classified as having no/mild diabetic
retinopathy also after an 8.7-year follow-up (controls). DNA methylation was also analyzed in a prospective cohort
including seven subjects with T1D who had no/mild diabetic retinopathy when blood samples were taken, but
who developed PDR within 6.3 years (converters). The retinopathy level was classified by fundus photography.
Results: We identified differential DNA methylation of 349 CpG sites representing 233 unique genes including TNF,
CHI3L1 (also known as YKL-40), CHN2, GIPR, GLRA1, GPX1, AHRR, and BCOR in cases with PDR compared with controls.
The majority of these sites (79 %) showed decreased DNA methylation in cases with PDR. The Natural Killer cell-mediated
cytotoxicity pathway was found to be significantly (P = 0.006) enriched among differentially methylated genes
in cases with PDR. We also identified differential DNA methylation of 28 CpG sites representing 17 genes (e.g. AHRR,
GIPR, GLRA1, and BCOR) with P <0.05 in the prospective cohort, which is more than expected by chance (P = 0.0096).
Conclusions: Subjects with T1D and PDR exhibit altered DNA methylation patterns in blood. Some of these epigenetic
changes may predict the development of PDR, suggesting that DNA methylation may be used as a prospective marker
of PDR.
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Table 1 Characteristics of cases with proliferative diabetic
retinopathy and controls included in the genome-wide analysis of
DNA methylation in blood from subjects with type 1 diabetes
Characteristics Controls Cases P value
N (male/female) 30 (15/15) 28 (17/11)
Age (years)* 36.1 ± 13.7 34.0 ± 8.5 1
Diabetes duration (years) 17.1 ± 9.6 21.0 ± 3.8 1 × 10−4
HbA1c (%) 7.1 ± 1.2 8.6 ± 1.6 2 × 10−4
Systolic blood pressure (mmHg) 126.7 ± 15.9 133.0 ± 21.4 0.44
Diastolic blood pressure (mmHg) 72.9 ± 9.9 77.0 ± 8.1 0.15
Data are presented a mean ± SD. P value based on Mann–Whitney two
independent samples test. *Age at DNA sampling and fundus photography
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Proliferative diabetic retinopathy (PDR) and macular edema
are the main causes of vision loss in subjects with diabetes
[1]. Subjects with type 1 diabetes (T1D) have a higher
prevalence of PDR than those with type 2 diabetes (T2D)
and key risk factors for development of PDR include hyper-
glycemia, diabetes duration, hypertension, and genetic
factors [1]. The Diabetes Control and Complications
Trial has shown that intensive glycemic control reduces
the incidence of PDR in subjects with T1D [2]. However,
after said trial, the Epidemiology of Diabetes Interventions
and Complications research group continued to follow the
same subjects and found that the measure of glycemic
control, HbA1c, deteriorated in the previously intensively
treated group of subjects, while it improved in the conven-
tionally treated one, so that the subsequent HbA1c levels
no longer differed during the 10-year follow-up period [3].
Yet the disparity in the cumulative incidence of further
progression of PDR between the groups continued to
increase, indicating that mechanisms underlying the
progressive alterations in retinal microvessels might be
long lasting [3]. It has been hypothesized that transient
peaks of hyperglycemia might be an independent risk
factor for progression of retinopathy in these subjects
and that hyperglycemic peaks may cause persistent epi-
genetic changes despite subsequent normoglycemia [4].
Epigenetic modifications, such as DNA methylation and
histone modifications, influence many cellular processes
including regulation of gene transcription, embryonic
development, X chromosome inactivation, and genomic
imprinting [5]. Altered epigenetic patterns may contribute
to disease development and differential DNA methylation
has been found in subjects with T1D and T2D compared
with non-diabetic controls [6–10]. Epigenetic modifications
may also influence the development of vascular complica-
tions in diabetic subjects and a recent study demonstrated
that differential DNA methylation was associated with
diabetic nephropathy [11]. However, whether epigenetic
modifications are associated with PDR in subjects with
T1D remains unknown. The aim of this study was therefore
to analyze the genome-wide DNA methylation pattern in
blood from subjects with T1D, including 28 cases with PDR
and 30 controls. Using a prospective cohort, we also tested
if changes in DNA methylation can be found in subjects




Study participants with T1D, diagnosed before 30 years
of age and insulin treatment within 1 year from diagno-
sis, were selected from the regional diabetes register
(Diabetes 2000) according to the following criteria: 1)
subjects with T1D for at least 10 years and classified ashaving no/mild diabetic retinopathy with, at most, a
few microaneurysms at initiation of the study (n = 37),
and 2) subjects with new-formed pathological retinal
vessels classified as having PDR (n = 28). All included
subjects had genomic DNA isolated from blood cells
available. The degree of retinopathy was verified by
available fundus photographs (EA) or by record infor-
mation on vitreous hemorrhage at the time of blood
sampling. The degree of retinopathy was thereafter estab-
lished approximately once per year by fundus photography.
After an approximately 6.3-year follow-up, seven out of
37 subjects had developed PDR, forming a prospective
follow-up cohort, and were classified as converters. Add-
itionally, after an approximately 8.7-year follow-up, 30 out
of 37 subjects were still without PDR and classified as con-
trols; the 28 subjects with PDR were classified as cases.
The characteristics of cases and controls are described in
Table 1 and of converters and controls in Additional file 1:
Table S1. The study was approved by the Regional Ethical
Committee (Lund University) and conducted in accord-
ance with the principles of the Helsinki Declaration. All
study participants gave written informed consent.
Genome-wide analysis of DNA methylation
The genome-wide DNA methylation analysis was per-
formed using the Infinium HumanMethylation450 Bead-
Chip (Illumina, San Diego, CA, USA), which contains
485,577 probes that cover 21,231 (99 %) RefSeq genes
[12]. Genomic DNA (500 ng) from blood was bisulfite
treated using the EZ DNA methylation kit (Zymo Re-
search, Orange, CA, USA) and subsequently used for
analysis of DNA methylation following the Infinium HD
Assay Methylation Protocol (Illumina). The BeadChips’
images were captured using the Illumina iScan. All in-
cluded samples showed a high quality bisulfite conver-
sion efficiency (intensity signal >4000) and passed all
GenomeStudio quality control steps based on built-in
control probes for staining, hybridization, extension,
and specificity. In total, 2,309 individual probes were
filtered away based on mean detection P >0.01 and 85
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methylation data was exported from GenomeStudio
and analyzed using Bioconductor and the lumi package.
Here, β-values were converted to M-values (M=log2(β/
(1-β))) [13]. Next, data was background corrected by
subtracting the median M-value of built in control probes
and normalized using quantile normalization [13]. The
DNA methylation array data were further corrected for
batch effects using COMBAT [13]. Finally, to more easily
interpret the results, M-values were reconverted to β-
values, which is used when describing the data and cre-
ating the figures. All identified significant CpG sites
with differences in DNA methylation between PDR
cases and controls were screened for cross-reactive
probes in the Illumina Infinium HumanMethylation450k
BeadChip [14].
Statistical analyses
We performed a principle component analysis of the
genome-wide DNA methylation data and correlated
the top five principle components with PDR, gender, age,
duration of diabetes, and HbA1c. To identify differences
in DNA methylation between cases with PDR and con-
trols, a logistic regression model was used, including
gender, age, and duration of diabetes as covariates and
DNA methylation as a quantitative variable. A false
discovery rate (FDR) analysis was used to correct for
multiple testing and a FDR less than 5 % (q <0.05) was
considered significant. Significant CpG sites were analyzed
in the prospective cohort using the same statistical model
and covariates, and presented if P <0.05.Results
Differential DNA methylation of specific CpG sites in
cases with PDR
To study the epigenetic basis of PDR in subjects with
T1D, DNA methylation of 480,079 CpG sites was ana-
lyzed in blood from 28 cases with PDR and 30 controls
using the Infinium HumanMethylation450 BeadChip.
The characteristics of the cases and controls included in
the genome-wide analysis of DNA methylation are de-
scribed in Table 1. Age was similar between the groups
but cases with PDR had longer diabetes duration and
higher HbA1c levels than controls (Table 1). To examine
the impact of these factors on DNA methylation, we
performed a principle component analysis of the genome-
wide DNA methylation data and correlated the top five
principle components with PDR, gender, age, duration
of diabetes, and HbA1c levels. While PDR, gender, age,
and duration of diabetes showed significant correlations
with one or several of the top five principle components
(P <0.05; Additional file 2: Table S2); HbA1c was not sig-
nificant in this analysis. Based on this result, we includedgender, age, and duration of diabetes as covariates in the
regression model where the association between PDR and
DNA methylation was studied. After correcting for mul-
tiple testing using a FDR analysis, we identified 349 CpG
sites representing 233 unique genes that were differentially
methylated between cases with PDR and controls (q <0.05;
Additional file 3: Table S3). We found decreased DNA
methylation in 276 sites (79 %) and increased DNA
methylation in 73 sites (21 %) in PDR cases. The absolute
differences in DNA methylation ranged from 0.08 % to
13.5 %, representing a fold change of 0.549 to 1.231 and
a 45.1 % decrease to a 23.1 % increase in methylation
in PDR cases compared with controls (Fig. 1a,b and
Additional file 3: Table S3). Based on a literature search,
genes with known functions in retina and eye development
(BCOR, GFI1, GLRA1, HDAC4, HMGA1, HTT, KLF5,
LAMA4, and SHANK1) [15], inflammation (AHRR, CCL1,
CD247, CD58, CD9, CXCR5, KDM1A, and SLC9A3R1)
[16], diabetic complications (ACTN4, ARG1, CHI3L1,
CHN2, CNP, GIPR, GPX1, KIFC1, NFE2, PEMT, RPS6KA2,
TNF, TNFAIP3, and TNFAIP8) [17], and oxidative stress
(AHRR, BACH2, GPX1, OXSR1, PFKFB3, and RCAN1)
[18] were among the genes that showed differential DNA
methylation in blood from T1D subjects with PDR
(Fig. 1c–f ). Some of these genes are represented in
several of the analyzed groups.
We then performed a pathway analysis of the 233 genes
with one or more CpG sites differentially methylated be-
tween cases with PDR and controls using WebGestalt
[19]. We found the KEGG pathway “Natural Killer cell
mediated cytotoxicity” to be significantly enriched in the
PDR cases (adjusted P = 0.006), including eight genes:
KLRD1, TNF, CD247, PIK3CD, GZMB, NFATC1, PRF1,
and KIR2DL4 (Table 2).Global DNA methylation in blood from cases with PDR
and controls
To evaluate the global methylome in blood from cases
with PDR and controls, we calculated the average level
of DNA methylation in the two groups based on either
the functional genome distribution (Fig. 1g) or the CpG
content and neighborhood context (Fig. 1h). The results
showed no significant differences in global DNA methyla-
tion between PDR cases and controls after FDR correction
(Fig. 1g,h, Additional file 4: Table S4). Nevertheless, the
average level of DNA methylation was high within the gene
body, 3′UTR, and in intergenic regions (60–75 %), whereas
it was lower in TSS1500 and 5′UTR (23–29 %) and lowest
within TSS200 and the first exon (12–14 %; Fig. 1g). In re-
lation to CpG islands, the average methylation was low
within the CpG island (15 %), intermediate in the shore re-
gions (43–44 %), and high in the shelf regions and open sea
(73–77 %; Fig. 1h).
Fig. 1 (See legend on next page.)
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Fig. 1 Number of CpG sites with significantly higher (a) or lower (b) DNA methylation in cases with PDR versus controls. Genes involved in retina
and eye development (c), inflammation (d), diabetic complications (e), and oxidative stress (f) were among the ones with one or more CpG sites
differentially methylated between cases with PDR and controls (q <0.05); data are presented as mean ± SD. Global DNA methylation is calculated
as average DNA methylation based on all CpG sites in each region on the chip and shows no differences between cases with PDR compared
with controls in mean methylation value based on gene regions (g) or regions in relation to nearest CpG island (h)
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We next tested if differences in DNA methylation may
be used as prospective markers of PDR in subjects with
T1D. Here, we used DNA from blood from T1D sub-
jects with no/mild diabetic retinopathy when the blood
samples were taken, but who developed PDR within
approximately 6 years (converters), and compared the
degree of DNA methylation in these converters with
methylation in control subjects who did not develop
PDR (controls; Additional file 1: Table S1). In this pro-
spective cohort there was no significant differences in dia-
betes duration between converters and controls, but the
converters had significantly lower age and higher HbA1c
levels (P <0.05; Additional file 1: Table S1) compared to
the controls. We examined if any of the 349 CpG sites
showing differential DNA methylation in the PDR cases
versus controls (Additional file 3: Table S3) also show dif-
ferential DNA methylation in the prospective cohort. We
found 28 sites representing 17 unique genes including
BCOR, GIPR, and GLRA1 that showed differential DNA
methylation in the same direction in the prospective co-
hort as well as in the case–control cohort with P ≤0.05
(Table 3). This is more than expected by chance based on
a χ2 test (P = 0.0096). However, the FDR analysis shows
that these sites are only nominally significant in the pro-
spective cohort (Table 3). The majority of these CpG sitesTable 2 Pathway analysis of genes with CpG sites differentially
methylated in cases with PDR versus controls
KEGG pathway: Natural Killer cell mediated cytotoxicity (P = 0.0001;
Padj = 0.0063)
Total # of genes in
pathway: 121
Expected # of genes: 1.48 Observed # of
genes: 8
Gene symbol Description
KLRD1 Killer cell lectin-like receptor subfamily D,
member 1




GZMB Granzyme B (granzyme 2, cytotoxic T-
lymphocyte-associated serine esterase 1)
NFATC1 Nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 1
PRF1 Perforin 1 (pore forming protein)
KIR2DL4 Killer cell immunoglobulin-like receptor, two
domains, long cytoplasmic tail, 4(93 %) exhibit lower methylation in the converters com-
pared with the controls.
Cross-reactive probes
As a quality control, we further screened the 349 sites
with significant differences in DNA methylation between
PDR cases and controls for cross-reactive probes in
the Illumina Infinium HumanMethylation450k BeadChip
[14]. Only one of the 349 probes had a perfect match else-
where in the genome and 13 probes matched for 47–49
out of 50 bases (Additional file 5: Table S5).
Association between HbA1c levels and DNA methylation
in blood
We finally tested if HbA1c was associated with differential
DNA methylation of individual CpG sites in the control
cohort including subjects with T1D without PDR. Gender,
age, and diabetes duration were included as covariates in
the linear regression model. However, after correction for
multiple testing using FDR, no significant association be-
tween HbA1c and DNA methylation was found (q = 0.99).
Additionally, HbA1c was only associated with methylation
of 14,522 CpG sites at P <0.05, which is much less than
expected by chance.
Even though HbA1c was not significantly associated
with DNA methylation based on this linear regression
analysis, nor based on the principle component analysis,
we tested to include HbA1c in the regression model for
the association between DNA methylation and PDR, as
there was a significant difference in HbA1c between PDR
cases and controls. Although not genome-wide significant
(q = 0.08–0.38), the 349 CpG sites detected to be differen-
tially methylated between PDR cases and controls in our
main analysis (q <0.05; Additional file 3: Table S3) all still
showed a strong nominal association (P = 4.0 × 10−7
to 7.6 × 10−3) after inclusion of HbA1c in the model
(Additional file 6: Table S6). Thereby, our results sup-
port that adjustment for HbA1c has no major effect
on the association between PDR and DNA methyla-
tion, but it makes the study less well powered since
the size of our study only supports the inclusion of up
to four variables in the regression analysis in order to
maintain statistical power. Additionally, when includ-
ing HbA1c in the model we found increased standard
errors in the regression analysis of all 349 CpG sites
(Additional file 6: Table S6), indeed suggesting that
this additional variable makes the model less stable.
Table 3 CpG sites showing significant differences in DNA methylation between cases with PDR and controls (FDR q <5 %,
Additional file 3: Table S3), that are also nominally differentially methylated in the same direction in the converters of the
prospective cohort at P <0.05
Location in relation to: DNA Methylation (%)
Probe ID Chr Nearest gene Gene region CpG Island Controls Converters Difference P value q value
cg26703534 5 AHRR Body S Shelf 63.6 ± 2.6 59.9 ± 4.1 −3.7 9.5 × 10−4 0.17
cg05575921 5 AHRR Body N Shore 82.4 ± 6.3 75.0 ± 8.1 −7.4 2.1 × 10−3 0.18
cg07339236 20 ATP9A Body Open sea 18.0 ± 2.5 15.6 ± 1.6 −2.4 0.013 0.35
cg05026884 X BCOR 5′UTR Island 26.5 ± 11.1 22.7 ± 4.7 −3.8 4.2 × 10−3 0.21
cg01490258 X BCOR 5′UTR N Shore 13.2 ± 2.9 12.4 ± 2.0 −0.8 0.010 0.33
cg23701759 X BCOR 5′UTR Island 34.9 ± 4.9 30.9 ± 3.7 −4.0 0.014 0.35
cg10055320 X BCOR 5′UTR N Shore 42.2 ± 4.4 39.2 ± 5.1 −3.0 0.029 0.50
cg00507154 19 C19orf76 1st Exon; 5′UTR Island 70.2 ± 4.6 67.7 ± 2.6 −2.5 0.030 0.50
cg08601628 8 C8orf74 Body Open sea 82.5 ± 3.0 80.6 ± 3.2 −1.9 0.022 0.43
cg12993916 6 DTNBP1 Body Open sea 78.9 ± 3.0 76.8 ± 3.7 −2.1 0.015 0.35
cg03636183 19 F2RL3 Body N Shore 68.9 ± 4.4 65.1 ± 4.7 −3.8 9.3 × 10−3 0.32
cg02942825 19 GIPR 3′UTR S Shore 49.8 ± 3.2 48.0 ± 5.8 −1.8 0.050 0.62
cg17808910 7 GLCCI1 Body S Shelf 73.7 ± 3.9 75.5 ± 4.6 1.8 0.048 0.62
cg26567012 5 GLRA1 3′UTR Open sea 55.4 ± 3.8 52.0 ± 6.0 −3.4 0.030 0.50
cg01010839 10 NET1 TSS1500; Body N Shore 71.2 ± 4.3 70.2 ± 2.2 −1.0 0.015 0.35
cg24796663 6 PHF1 TSS1500 N Shore 12.9 ± 1.8 11.3 ± 1.9 −1.6 1.5 × 10−3 0.17
cg11224624 8 PLEC1 Body Island 2.1 ± 0.3 2.3 ± 0.3 0.2 0.033 0.52
cg22291265 19 SHANK1 Body Open sea 7.5 ± 2.3 6.9 ± 1.3 −0.6 0.050 0.62
cg06589051 2 TGFBRAP1 TSS1500 S Shore 72.4 ± 2.0 70.2 ± 4.1 −2.2 0.040 0.61
cg08597832 8 TOP1MT Body N Shore 82.1 ± 2.5 79.8 ± 2.7 −2.3 0.020 0.41
cg11166303 2 TSSC1 Body N Shore 67.8 ± 7.5 61.2 ± 8.5 −6.6 4.0 × 10−3 0.21
cg09577317 8 Intergenic N Shore 83.9 ± 1.6 81.0 ± 1.2 −2.9 1.7 × 10−4 0.058
cg07948143 14 Intergenic Open sea 75.5 ± 3.2 71.0 ± 4.6 −4.5 2.9 × 10−3 0.20
cg24058013 18 Intergenic Island 89.8 ± 1.0 87.7 ± 1.8 −2.1 5.4 × 10−3 0.24
cg03889263 3 Intergenic Open sea 20.0 ± 3.9 15.9 ± 2.6 −4.1 6.9 × 10−3 0.27
cg05546763 14 Intergenic Island 82.0 ± 2.0 80.6 ± 2.3 −1.4 0.016 0.36
cg15342087 6 Intergenic Open sea 81.1 ± 2.1 80.2 ± 2.2 −0.9 0.046 0.62
cg06126421 6 Intergenic Open sea 69.2 ± 6.2 69.0 ± 4.4 −0.2 0.050 0.62
Data are presented a mean ± SD
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In the present study, we demonstrate for the first time
that differential DNA methylation in/near 233 unique
genes is associated with PDR in a case–control cohort.
In a prospective cohort, we also found epigenetic markers
that can predict PDR. Our study suggests that DNA
methylation in blood can be used as a predictive bio-
marker of PDR in subjects with T1D. However, replication
studies are needed to verify our results.
Diabetic retinopathy is a common microvascular com-
plication and, in its severe forms, the leading cause of
blindness among working-aged adults in the western
world [1]. In PDR, ischemia is preceding formation of new
vessels, which untreated can result in vitreous hemorrhageand retinal detachment. Inflammation does also play a key
role in development of microvascular diabetic compli-
cations, including PDR [17]. Subjects with T1D have a
relatively high prevalence of diabetic retinopathy com-
pared with subjects with T2D and it is well established
that HbA1c levels, diabetes duration, and hypertension
increase the risk for PDR [20]. Previous studies have
tried to identify biomarkers that can be used to clinically
predict diabetic retinopathy in subjects with diabetes [21].
However, so far, limited breakthroughs have taken place
[22–24]. In our study, we chose to identify markers, not
for diabetic retinopathy per se but for the most severe
consequence of ischemic retinopathy, i.e. PDR. Since dia-
betes duration and degree of non-proliferative retinopathy
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ing control subjects with as low risk as possible. It was not
possible to identify a sufficient number of control subjects
with at least 10 years of diabetes who were also completely
without microaneurysms, but as occasional microaneur-
ysms may come and go we included subjects with a few
microaneurysms. Using a longitudinal approach, we could
conclude that 81 % (30 out of 37 subjects) of these sub-
jects still were without PDR approximately 8 years later
and they were assigned as controls. Progression to PDR
occurred in seven subjects (19 %) and were assigned
converters. Those subjects differed from both cases and
controls by younger age and poorer metabolic control
measured by HbA1c. Those characteristics are associated
with a high risk for the rapid development of severe PDR,
also known as florid retinopathy [25], which results in se-
vere visual impairment or blindness if not properly treated
in time. Based on our study design, we have been able not
only to identify epigenetic markers associated with PDR
but also predictive of the most severe form of diabetic
retinopathy in T1D.
We identified 349 CpG sites representing 233 genes
with altered DNA methylation levels in T1D subjects
with PDR. The majority of these sites (79 %) showed
decreased DNA methylation in cases with PDR. A lower
methylation level may be associated with higher expres-
sion as DNA methylation has been shown to repress the
binding of transcription factors to promoter regions and
attract proteins such as transcriptional co-repressors and
histone deacetyltransferases associated with a dense chro-
matin structure and inactive genes [5]. Although it would
have been interesting to also study gene expression in
the present case–control cohort, this was not possible
since only DNA was extracted when blood was collected.
Nevertheless, DNA methylation in blood can quite easily
be used as a biomarker that predicts disease and the epi-
genetic alterations found in the present study suggest that
this may be possible in subjects with T1D.
Several identified genes with altered DNA methylation
in cases with PDR, such as TNF, CHI3L1, and CHN2, en-
code proteins with previous known function in diabetic
complications and/or diabetic retinopathy [17]. TNF, which
encodes tumor necrosis factor, exhibits decreased DNA
methylation in cases with PDR. Tumor necrosis factor is a
proinflammatory cytokine that is elevated in serum from
subjects with PDR [26]. Epigenetic modifications of TNF in
T1D subjects may subsequently regulate the expression of
TNF and thereby contribute to inflammation in diabetic
retinopathy. CHI3L1, also known as YKL-40, encodes
an inflammatory glycoprotein involved in endothelial
dysfunction and cardiovascular disease [27]. We found
decreased DNA methylation of CHI3L1 in cases with
PDR, which may contribute to increased expression of this
gene. Interestingly, serum levels of YKL-40 were elevatedin subjects with diabetic retinopathy [28] and ischemia
was associated with higher YKL-40 mRNA levels in ca-
rotid plaque [29]. As ischemia precedes PDR, it may
also affect methylation and/or expression of CHI3L1 in
subjects with diabetic retinopathy. Cases with PDR also
exhibited decreased DNA methylation of CHN2, which
encodes chimerin 2, a protein known to affect prolifera-
tion and migration of smooth muscle cells. Interestingly, a
SNP in an intron of CHN2 was recently associated with
diabetic retinopathy in Chinese people with T2D, further
supporting a role for this gene in the development of
diabetic retinopathy [30].
The largest absolute difference in DNA methylation
between PDR cases and controls was 13.5 %, which rep-
resents a fold change of 1.22. Our epigenetic data are in
line with previous genetic studies where the odds ratio
of most genetic variants associated with PDR has been
modest [31]. However, we identified more than 200 genes
with differential DNA methylation in PDR cases after cor-
rection for multiple testing and it is possible that modest
changes of multiple genes together contribute to the disease
phenotype. The present study is, to our knowledge, the first
one to analyze DNA methylation genome-wide in subjects
with PDR. However, a previous study by Bell et al. [11] also
reported absolute differences in DNA methylation of ap-
proximately 10 % when DNA methylation of approximately
27,000 sites was analyzed in blood from subjects with
diabetic nephropathy.
In order to assess if epigenetic modifications may be
used as biomarkers that predict PDR, we analyzed DNA
methylation in a prospective cohort. Differential DNA
methylation may predict PDR as several epigenetic
modifications identified in cases with PDR were also
found in our prospective cohort. BCOR encoding BCL6 co-
repressor has the most CpG sites differentially methylated
in both the case–control cohort and in the prospective co-
hort. While these data suggest that epigenetic modifications
of BCOR may be used to predict PDR, larger prospective
studies are needed to further validate our findings. GIPR,
encoding glucose-dependent insulinotropic polypeptide
receptor, also showed decreased DNA methylation in
our prospective cohort as well as in the cases with
PDR, and may subsequently be used as a candidate gene
that predicts PDR. Interestingly, a previous study found
increased expression of the GIPR in the retinas of
streptozotocin-induced diabetic rats [32]. However,
whether expression of the GIPR is increased in the human
retina of diabetic subjects remains unknown and will be
ethically difficult to analyze. The prospective cohort also
confirmed demethylation of the aryl hydrocarbon receptor
repressor (AHRR) in PDR cases, a locus which has been
repeatedly shown to associate with smoking [33–35]. Un-
fortunately, we do not have access to smoking status in
our study from when samples were collected and hence
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the groups may affect this association.
Our study supports a role of epigenetic variation in
the pathogenesis of PDR. Furthermore, the heritability of
PDR has been estimated to 27 % and genetic variants
may thereby affect the risk for PDR [36]. However, al-
though genome-wide association studies have been per-
formed to identify genetic variants associated with PDR,
the outcome from these studies was limited [36–38]. It
is possible that genetic variants interact with epigenetic
variation to increase the risk for disease [39, 40]. How-
ever, further genome-wide studies are needed to dissect
whether interactions between genetics and epigenetics
play a role in PDR.
Conclusion
Together, our study is the first to identify epigenetic
modifications in T1D subjects with PDR. Our data suggest
that differential DNA methylation may contribute to
the pathogenesis of PDR in subjects with T1D and that
DNA methylation in blood may be used as a predictive
biomarker for this severe type of diabetic retinopathy.
However, replication is needed to establish whether the
findings really represent a novel biomarker of retinopathy
risk.
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